176 related articles for article (PubMed ID: 34820734)
1. The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
Di Sabatino E; Gaetani L; Sperandei S; Fiacca A; Guercini G; Parnetti L; Di Filippo M
J Neurol; 2022 Jun; 269(6):3129-3135. PubMed ID: 34820734
[TBL] [Abstract][Full Text] [Related]
2. Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis.
Lim TRU; Kumaran SP; Suthiphosuwan S; Espiritu AI; Jones A; Lin AW; Oh J; Bharatha A
Mult Scler; 2024 Apr; 30(4-5):505-515. PubMed ID: 38419027
[TBL] [Abstract][Full Text] [Related]
3. Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis.
Tummala S; Singhal T; Oommen VV; Kim G; Khalid F; Healy BC; Bakshi R
Int J MS Care; 2017; 19(3):158-164. PubMed ID: 28603465
[TBL] [Abstract][Full Text] [Related]
4. The course of cervical spinal cord atrophy rate and its relationship with NEDA in relapsing remitting multiple sclerosis.
Cilingir V; Akdeniz H
Acta Neurol Belg; 2022 Apr; 122(2):345-355. PubMed ID: 33475987
[TBL] [Abstract][Full Text] [Related]
5. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
Zafar A; AlShamrani FJG
Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
[TBL] [Abstract][Full Text] [Related]
6. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
Vermersch P; Oreja-Guevara C; Siva A; Van Wijmeersch B; Wiendl H; Wuerfel J; Buffels R; Kadner K; Kuenzel T; Comi G;
Eur J Neurol; 2022 Mar; 29(3):790-801. PubMed ID: 34748672
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
9. Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort.
Ozakbas S; Piri Cinar B; Baba C; Kosehasanogullari G; Sclerosis Research Group M
Acta Neurol Scand; 2022 May; 145(5):557-564. PubMed ID: 35043388
[TBL] [Abstract][Full Text] [Related]
10. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
[TBL] [Abstract][Full Text] [Related]
11. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
12. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
[TBL] [Abstract][Full Text] [Related]
13. The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study.
Dallera G; Affinito G; Caliendo D; Petracca M; Carotenuto A; Triassi M; Brescia Morra V; Palladino R; Moccia M
Mult Scler Relat Disord; 2023 Jan; 69():104423. PubMed ID: 36436395
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.
Bazzurri V; Fiore A; Curti E; Tsantes E; Franceschini A; Granella F
Mult Scler Relat Disord; 2023 Nov; 79():105015. PubMed ID: 37769430
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
16. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
17. Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis.
Tsantes E; Curti E; Collura F; Bazzurri V; Fiore A; Granella F
J Neurol Sci; 2020 Jul; 414():116827. PubMed ID: 32289575
[TBL] [Abstract][Full Text] [Related]
18. Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey.
Granella F; Tsantes E; Graziuso S; Bazzurri V; Crisi G; Curti E
J Neurol; 2019 Dec; 266(12):3031-3037. PubMed ID: 31494713
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study.
Horakova D; Uher T; Krasensky J; Seidl Z; Ribbens A; Van Hecke W; Billiet T; Koendgen H; Freudensprung U; Hyde R; Vaneckova M
Mult Scler Relat Disord; 2020 Nov; 46():102543. PubMed ID: 33296966
[TBL] [Abstract][Full Text] [Related]
20. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
Szilasiová J; Mikula P; Rosenberger J; Fedičová M; Gdovinová Z; Urban P; Frigová L
Mult Scler; 2021 Nov; 27(13):2023-2030. PubMed ID: 33635154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
